Testing effectiveness (Phase 2)Study completedNCT02162446What this trial is testing68Ga-OPS202 Study for Diagnostic Imaging of GEP NETWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Ipsen 12
Testing effectiveness (Phase 2)Ended earlyNCT02489604What this trial is testingPeptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 70
Not applicableUnknownNCT01201096What this trial is testingNeo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)Who this might be right forLiverMetastasisNeuroendocrine Tumors University of Jena 50
Not applicableStudy completedNCT02150408What this trial is testingEvaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine TumorsWho this might be right forGastro-Entero-Pancreatic Tumors (GEPs) Assistance Publique Hopitaux De Marseille 35
Testing effectiveness (Phase 2)UnknownNCT04029428What this trial is testingPeptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR OverexpressionWho this might be right forNeuroendocrine Tumors University of Warmia and Mazury 150
Testing effectiveness (Phase 2)Ended earlyNCT02736448What this trial is testing177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine TumorsWho this might be right forGastro-entero-pancreatic Neuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)UnknownNCT04194125What this trial is testingPersonalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine CancerWho this might be right forNeuroendocrine Tumors University of Warmia and Mazury 25
Testing effectiveness (Phase 2)Study completedNCT02736500What this trial is testingPeptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine TumorsWho this might be right forNeuroendocrine TumorsGastro Entero Pancreatic Neuroendocrine Tumors Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 39
Testing effectiveness (Phase 2)UnknownNCT02409849What this trial is testingOctreotide LAR as Maintenance Treatment for Patients With NECWho this might be right forGastro-entero-pancreatic CarcinomaEsophageal Neuroendocrine Carcinoma Peking University 92
Not applicableStudy completedNCT03288402What this trial is testingInvestigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET PatientsWho this might be right forNeuroendocrine Tumors University Hospitals Coventry and Warwickshire NHS Trust 346
Not applicableLooking for participantsNCT06519500What this trial is testingGeneration of Organoids of Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic Tract Obtained From Patients Undergoing SurgeryWho this might be right forGastro-entero-pancreatic Neoplasms Regina Elena Cancer Institute 40
Testing effectiveness (Phase 2)Looking for participantsNCT04325425What this trial is testingChemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown PrimaryWho this might be right forNeuroendocrine Carcinoma Centre Hospitalier Universitaire Dijon 218
Not applicableStudy completedNCT04727723What this trial is testingItalian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETsWho this might be right forGastroenteropancreatic Neuroendocrine Tumor Novartis Pharmaceuticals 164
Not applicableLooking for participantsNCT04949282What this trial is testingSpanish Series of Patients Treated With the Radionuclide Lutetium177Who this might be right forNeuroendocrine TumorsIntestinal NeoplasmsPancreatic Neoplasms+15 more Sociedad Española de Medicina Nuclear e Imagen Molecular 5,000
Not applicableLooking for participantsNCT04282083What this trial is testingProtocol ITANET - RegistryWho this might be right forGastro-entero Pancreatic Neuroendocrine Tumors Italian Association Neuroendocrine Tumors 3,600
Not applicableLooking for participantsNCT06735560What this trial is testingStudy Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NENWho this might be right forHepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Neuroendocrine Tumors Nantes University Hospital 60
Testing effectiveness (Phase 2)Study completedNCT02231762What this trial is testingCombination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETWho this might be right forGastroenteropancreatic Neuroendocrine Tumors Ipsen 57
Not applicableNot Yet RecruitingNCT06344832What this trial is testingSSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETsWho this might be right forGastro-entero-pancreatic Neuroendocrine Tumor Peking Union Medical College Hospital 40